Physician profile
Lida N Osbern
NPI 1427153006
$1,689.50
in general payments reported to CMS, 2019-2025
30 companies · $411 in 2025
The $411 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $200 · 2023: $266 · 2024: $126 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Education: $36.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.63 |
| Education | $36.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $243.85 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $205.90 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.52 | 2019-2023 | Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $132.32 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $103.61 | 2019-2023 | Prolastin-C Liquid |
| Amgen INC. | $103.03 | 2019-2025 | Tezspire |
| Mylan Specialty L.P. | $97.03 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $91.35 | 2019 | |
| Viatris Specialty LLC | $76.76 | 2025 | Yupelri |
| Scilex Pharmaceuticals INC. | $40.15 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $39.33 | 2019-2025 | Camzyos |
| Amarin Pharma, INC. | $39.32 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.86 | 2025 | Lifevest |
| Insmed, INC. | $34.28 | 2025 | Brinsupri, Arikayce |
| Novo Nordisk INC | $24.83 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.48 | 2019 | |
| Electromed, INC. | $24.41 | 2024 | Smartvest |
| Verona Pharma, INC. | $24.21 | 2025 | Ohtuvayre |
| Inogen, INC. | $23.58 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $20.48 | 2019 | |
| Resmed Corp | $19.36 | 2024 | |
| Axsome Therapeutics, INC. | $17.94 | 2024 | Sunosi |
| Jazz Pharmaceuticals INC. | $14.06 | 2019 | |
| Advanced Respiratory, INC | $13.80 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.49 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.43 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.12 | 2020 | |
| 3b Medical, INC. | $11.99 | 2023 | Luna |
| Monaghan Medical Corporation | $11.53 | 2023 | Aerobika |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lida Osbern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.